IPSEN (OTCMKTS:IPSEY) Stock Price Up 7.1% – Time to Buy?

IPSEN (OTCMKTS:IPSEY)’s stock price shot up 7.1% during trading on Friday. The stock traded as high as $43.85 and last traded at $43.85. Approximately 1,175 shares traded hands during mid-day trading, a decline of 41% from the average session volume of 1,991 shares. The stock had previously closed at $40.93.

Analyst Ratings Changes

A number of research firms have weighed in on IPSEY. Barclays upgraded IPSEN from a “strong sell” rating to a “hold” rating in a research note on Thursday, September 17th. HC Wainwright reaffirmed a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Finally, Jefferies Financial Group downgraded IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold”.

IPSEN Trading Up 2.0%

The firm’s 50-day moving average price is $44.38 and its two-hundred day moving average price is $46.03.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.